| Autor: |
Gu Y; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Becker MA; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Müller L; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Reuss K; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Umlauf F; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Tang T; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Menger MD; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany., Laschke MW; Institute for Clinical & Experimental Surgery, Saarland University, 66421 Saar, Germany. |
| Abstrakt: |
Tumor endothelial cells (TECs) are key stromal components of the tumor microenvironment, and are essential for tumor angiogenesis, growth and metastasis. Accumulating evidence has shown that small single-stranded non-coding microRNAs (miRNAs) act as powerful endogenous regulators of TEC function and blood vessel formation. This systematic review provides an up-to-date overview of these endothelial miRNAs. Their expression is mainly regulated by hypoxia, pro-angiogenic factors, gap junctions and extracellular vesicles, as well as long non-coding RNAs and circular RNAs. In preclinical studies, they have been shown to modulate diverse fundamental angiogenesis-related signaling pathways and proteins, including the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway; the rat sarcoma virus (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway; the phosphoinositide 3-kinase (PI3K)/AKT pathway; and the transforming growth factor (TGF)-β/TGF-β receptor (TGFBR) pathway, as well as krüppel-like factors (KLFs), suppressor of cytokine signaling (SOCS) and metalloproteinases (MMPs). Accordingly, endothelial miRNAs represent promising targets for future anti-angiogenic cancer therapy. To achieve this, it will be necessary to further unravel the regulatory and functional networks of endothelial miRNAs and to develop safe and efficient TEC-specific miRNA delivery technologies. |
